Somatostatin receptors are useful drug targets for therapy aimed at the treatment of humoral
effects of certain tumors. Radiolabeled somatostatin analogs, such as octreotide, with a high …

The challenge for internal therapy is to deliver the highest possible dose to the tumor while
sparing normal organs from damage. Currently, the potential risk of kidney and red marrow …

This article reviews the results of somatostatin receptor imaging (SRI) in patients with
somatostatin receptor–positive neuroendocrine tumors, such as pituitary tumors, endocrine …

In the 1980s, the 111In-labeled somatostatin analog OctreoScan (Covidien, Hazelwood,
MO) was developed for imaging of somatostatin receptor subtype 2 (sst2) overexpressing …

A new treatment modality for inoperable or metastasized gastroenteropancreatic tumors is
the use of radiolabeled somatostatin analogs. Initial studies with high doses of [111 In …

Radiolabeled peptides targeted against receptors on the cell surface have been shown to
be remarkably specific and effective in the diagnosis and therapy of malignant disease …

Peptide receptor radionuclide therapy (PRRT) has been constantly evolving over the last
decade, pro-viding successful results in the treatment of tumors expressing somatostatin …

Regulatory peptide receptors are overexpressed in numerous human cancers. The specific
receptor binding property of peptides can be exploited by their labelling with a radionuclide …

Preclinical and clinical studies have indicated that somatostatin receptor (sst)–expressing
tumors demonstrate higher uptake of radiolabeled sst antagonists than of sst agonists. In 4 …

Purpose Renal irradiation is a dose-limiting factor in peptide receptor radionuclide therapy
using radiolabelled somatostatin analogues. This irradiation is mainly caused by …